Bexion Pharmaceuticals, Inc.
6
0
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
50.0%
3 terminated/withdrawn out of 6 trials
40.0%
-46.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
Role: lead
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
Role: lead
Continued Treatment for Participants Enrolled in Studies of BXQ-350
Role: lead
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Role: lead
Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors
Role: lead
A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors
Role: lead
All 6 trials loaded